Telmisartan Market Size Worth $4 billion by 2026 - KBV Research

The Hypertension market dominated the Global Telmisartan Market by Indication in 2019, thereby, growing at a CAGR of 5.7 % during the forecast period. The Cardiovascular Risk Reduction market is estimated to grow at a CAGR of 6.9% during (2020 - 2026).

The online pharmacies segment would display a substantial growth rate over the forecast years. It is owing to a rise in awareness of online pharmacy, shifting preferences towards online purchasing of drugs, and increasing internet users. In addition, the growth of the segment would be further augmented by the several benefits offered by online pharmacies including low expenses, more convenience, high accessibility to patient reviews, and easy price comparisons.

The North America market dominated the Global Telmisartan Market by Region in 2019. The Europe market is estimated to grow at a CAGR of 5.4% during (2020 - 2026). Asia-Pacific brings attractive growth opportunities for leading players working in the telmisartan market. This is due to a surge in the number of hypertension patients in developing countries, a surge in the adoption of antihypertensive drugs, advancements in the R&D sector, and various reforms in the healthcare sector, and technological developments in pharmaceutical drug manufacturing. In addition, the growth of the global Telmisartan would be boosted by the surging demand for telmisartan tablets, increasing investment from government & non-government sectors to spread awareness regarding hypertension and cardiovascular diseases, a surge in the number of hospital pharmacies and online pharmacies, and high population density.

Full Report: https://www.kbvresearch.com/telmisartan-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cipla Limited, GlaxoSmithKline PLC (GSK), Mylan N.V., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Cadila Healthcare Ltd. (Zydus Cadila).

Global Telmisartan Market Segmentation

By Indication

• Hypertension


• Cardiovascular Risk Reduction

By Distribution Channel

• Hospital Pharmacies


• Drug Stores & Retail Pharmacies


• Online Pharmacies

By Geography

North America

• US


• Canada


• Mexico


• Rest of North America

Europe

• Germany


• UK


• France


• Russia


• Spain


• Italy


• Rest of Europe

Asia Pacific

• China


• Japan


• India


• South Korea


• Singapore


• Malaysia


• Rest of Asia Pacific

LAMEA

• Brazil


• Argentina


• UAE


• Saudi Arabia


• South Africa


• Nigeria


• Rest of LAMEA

Companies Profiled

• Abbott Laboratories


• Aurobindo Pharma Limited


• Boehringer Ingelheim International GmbH


• Cipla Limited


• GlaxoSmithKline PLC (GSK)


• Mylan N.V.


• Sanofi S.A.


• Sun Pharmaceutical Industries Ltd.


• Teva Pharmaceuticals Industries Ltd.


• Cadila Healthcare Ltd. (Zydus Cadila)